|
|
|
|
LEADER |
00000cam a2200000Ia 4500 |
001 |
SCIDIR_ocn268694280 |
003 |
OCoLC |
005 |
20231117015126.0 |
006 |
m o d |
007 |
cr cnu---unuuu |
008 |
081103s1991 caua ob 001 0 eng d |
040 |
|
|
|a N$T
|b eng
|e pn
|c N$T
|d OCLCQ
|d UBY
|d IDEBK
|d E7B
|d OCLCQ
|d OPELS
|d OCLCQ
|d OCLCF
|d EBLCP
|d YDXCP
|d OCLCQ
|d UAB
|d MERUC
|d OCLCQ
|d LEAUB
|d OCLCQ
|d OCLCO
|d OCLCQ
|d INARC
|d OCLCO
|
019 |
|
|
|a 505149346
|a 646754426
|a 808683963
|
020 |
|
|
|a 9780080581132
|q (electronic bk.)
|
020 |
|
|
|a 0080581137
|q (electronic bk.)
|
020 |
|
|
|a 0120329220
|q (electronic bk.)
|
020 |
|
|
|a 9780120329229
|q (electronic bk.)
|
035 |
|
|
|a (OCoLC)268694280
|z (OCoLC)505149346
|z (OCoLC)646754426
|z (OCoLC)808683963
|
050 |
|
4 |
|a RM30
|b .A4eb vol. 22
|
072 |
|
7 |
|a MED
|x 023000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 072000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 058170
|2 bisacsh
|
082 |
0 |
4 |
|a 615/.1
|2 22
|
096 |
|
|
|a QV 4
|f ADV
|
245 |
0 |
0 |
|a Advances in pharmacology.
|n Volume 22 /
|c edited by J. Thomas August, M.W. Anders, Ferid Murad.
|
260 |
|
|
|a San Diego :
|b Academic Press :
|b Harcourt Brace Jovanovich,
|c �1991.
|
300 |
|
|
|a 1 online resource (x, 374 pages) :
|b illustrations.
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
490 |
0 |
|
|a Advances in pharmacology ;
|v v. 22
|
504 |
|
|
|a Includes bibliographical references and index.
|
588 |
0 |
|
|a Print version record.
|
505 |
0 |
|
|a Cover; Contents; Contributors; Chapter 1. Acyclovir: Mechanism of Antiviral Action and Potentiation by Ri bonucleotide Reductase Inhibitors; I. Introduction; II. Acyclovir Transport; III. Metabolic Activation of Acyclovir; IV. Mechanism of Antiviral Action; V. Potentiation of the Antiviral Action of Acyclovir; VI. Resistance and Hypersensitivity to Acyclovir; VII. Conclusions; References; Chapter 2. Rational Approaches to Osteoporosis Therapy; I. Introduction; II. Age-Related Changes in Bone Mass; III. Mechanisms of Bone Mass Regulation; IV. Osteoporosis; V. Experimental Approaches.
|
505 |
8 |
|
|a VI. Nonpharmacological ConsiderationsVII. Conclusions; References; Chapter 3. Molecular Asymmetry and Its Pharmacological Consequences; I. Introduction; II. Pharmacokinetic Consequences of Chirality; III. Chirality and Polymorphic Drug Disposition; IV. Pharmacodynamic Consequences of Chirality; V. Enantiomer-Enantiomer Interactions; VI. Enantioselective Drug-Enantiomer Interactions; VII. Enantiomeric Impurity and Potential Problems; VIII. Enantiomers as Biochemical Probes; IX. Therapeutic and Regulatory Considerations; X. Therapeutic Drug Monitoring; XI. Conclusions; References.
|
505 |
8 |
|
|a Chapter 4. Blood-Brain Barrier: Transport Studies in Isolated Brain Capillaries and in Cultured Brain Endothelial CellsI. Introduction; II. Establishment and Characterization of an in Vitro Blood-Brain Barrier Model; III. In Vitro Transport Studies; IV. In Vitro Studies on Regulation of Blood-Brain Barrier Transport; V. Summary; References; Chapter 5. Protein Kinase Inhibitors: Probes for the Functions of Protein Phosphorylation; I. Introduction; II. Inhibitors of Protein Serine/Threonine Kinases; III. Inhibitors of Protein Tyrosine Kinases; IV. Concluding Remarks; References.
|
505 |
8 |
|
|a Chapter 6. Renin InhibitorsI. Introduction; II. Physical and Functional Properties of Renin; III. Biochemical Evaluation and Specificity of Renin Inhibitors; IV. Design and Structure of Renin Inhibitors; V. Pharmacology of Renin Inhibitors; VI. Conclusion; References; Chapter 7. The Capacitative Model for Receptor-Activated Calcium Entry; I. Introduction; II. Epithelial Cells: Models for Studying Receptor-Activated Ca2+ Signaling; III. Mechanisms of Ca2+ Entry; IV. Conclusions; References; Chapter 8. Calcium Channel Antagonists in the Prevention of Neurotoxicity; I. Introduction.
|
505 |
8 |
|
|a II. Potential Problems in Interpreting the Effectiveness of Calcium Channel Antagonists in Preventing NeurotoxicityIII. Types of Neurotoxicity Attenuated by Calcium Channel Antagonists; IV. The Hypothesis of Calcium-Associated Neuronal Damage; V. Potential Contribution of T, N, L, and P Types of Calcium Channels to Neurotoxicity; VI. Types of Voltage-Dependent Calcium Channel Antagonists; VII. In Vitro Models of Neurotoxicity and Effects of Calcium Channel Antagonists; VIII. In Vivo Animal Models of Ischemia and Effects of Calcium Channel Antagonists.
|
520 |
|
|
|a ADVANCES IN PHARMACOLOGY VOL 22.
|
650 |
|
0 |
|a Pharmacology.
|
650 |
|
2 |
|a Pharmacology
|0 (DNLM)D010600
|
650 |
|
4 |
|a Drug therapy
|v Periodicals.
|
650 |
|
4 |
|a Drug therapy.
|
650 |
|
4 |
|a Pharmacology
|v Periodicals.
|
650 |
|
4 |
|a Pharmacology.
|
650 |
|
6 |
|a Pharmacologie.
|0 (CaQQLa)201-0007219
|
650 |
|
7 |
|a pharmacology.
|2 aat
|0 (CStmoGRI)aat300137970
|
650 |
|
7 |
|a MEDICAL
|x Drug Guides.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Pharmacology.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Pharmacy.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Nursing
|x Pharmacology.
|2 bisacsh
|
650 |
|
7 |
|a Pharmacology
|2 fast
|0 (OCoLC)fst01060259
|
650 |
|
7 |
|a Pharmacologie.
|2 fmesh
|
655 |
|
4 |
|a Electronic books.
|
700 |
1 |
|
|a August, J. Thomas.
|
700 |
1 |
|
|a Anders, M. W.
|q (Marion Walter),
|d 1936-
|
700 |
1 |
|
|a Murad, Ferid.
|
776 |
0 |
8 |
|i Print version:
|t Advances in pharmacology. Volume 22.
|d San Diego : Academic Press : Harcourt Brace Jovanovich, �1991
|z 0120329220
|z 9780120329229
|w (OCoLC)25660610
|
856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780120329229
|z Texto completo
|